Replies to post #109436 on Biotech Values

[DewDiligence]

…previously you posted (IIRC) that you do not foresee an at-risk launch of a generic Copaxone. Do you still believe this, and could you explain your basis?

I think NVS/MNTA would be willing to launch following a favorable ruling by the District Court, taking a chance that the decision could be reversed on appeal. However, I don’t think NVS/MNTA would be willing to launch without a favorable ruling by the District Court because this might subject them to treble damages for Teva’s lost profits if NVS/MNTA ended up losing the case.